BRPI0606319A2 - compostos farmacêuticos - Google Patents

compostos farmacêuticos

Info

Publication number
BRPI0606319A2
BRPI0606319A2 BRPI0606319-5A BRPI0606319A BRPI0606319A2 BR PI0606319 A2 BRPI0606319 A2 BR PI0606319A2 BR PI0606319 A BRPI0606319 A BR PI0606319A BR PI0606319 A2 BRPI0606319 A2 BR PI0606319A2
Authority
BR
Brazil
Prior art keywords
hydrogen
alkoxy
halogen
optionally substituted
carbocyclic
Prior art date
Application number
BRPI0606319-5A
Other languages
English (en)
Inventor
Jayne Elizabeth Curry
John Francis Lyons
Matthew Simon Squires
Paul Graham Wyatt
Neil Thomas Thompson
Kyla Merriom Thompson
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of BRPI0606319A2 publication Critical patent/BRPI0606319A2/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J1/00—Details of electrodes, of magnetic control means, of screens, or of the mounting or spacing thereof, common to two or more basic types of discharge tubes or lamps
    • H01J1/02—Main electrodes
    • H01J1/30—Cold cathodes, e.g. field-emissive cathode

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPOSTOS FARMACêUTICOS. A presente invenção fornece uma combinação de um composto tendo a fórmula (O) e dois ou mais outros agentes anticâncer: ou sais ou tautómeros ou N-óxidos ou solvatos destes; em que X é um grupo R^ 1^-A-NR^ 4^- ou um anel carbocíclico ou heterocíclico de 5 ou 6 membros; A é uma ligação, SO~ 2~, C=0, NR^ g^(C=O) ou 0(0=0), em que R^ g^ é hidrogênio ou C~ 1-4~ hidrocarbila opcionalmente substituida por hidróxi ou C~ 1-4~ alcóxi; Y é uma ligação ou uma cadeia de alquileno de 1, 2 ou 3 átomos de carbono em comprimento; R^ 1^ é hidrogênio; um grupo carbocíclico ou heterocíclico tendo de 3 a 12 membros de anel; ou um grupo C~ 1-8~ hidrocarbila opcionalmente substituído por um ou mais substituintes selecionados a partir de halogênio (por exemplo, flúor), hidróxi, C~ 1-4~ hidrocarbilóxi, amino, mono ou di-C~ 1-4~ hidrocarbilamino, e grupos carbocíclicos ou heterocíclicos tendo de 3 a 12 membros de anel, e, em que 1 ou 2 dos átomos de carbono do grupo hidrocarbila podem opcionalmente ser substituidos por um átomo ou grupo selecionado a partir de O, S, NH, SO, SO~ 2~; R^ 2^ é hidrogênio; halogênio; C~ 1-4~ alcóxi (por exemplo, metóxi); ou um grupo C~ 1-4~ hidrocarbila opcionalmente substituído por halogênio (por exemplo, flúor), hidroxila ou C~ 1-4~ alcóxi (por exemplo, metóxi); R^ 3^ é selecionado a partir de hidrogênio e grupos carbocíclicos e heterocíclicos tendo de 3 a 12 membros de anel; e R^ 4^ é hidrogênio ou um grupo C~ 1-4~ hidrocarbila opcionalmente substituído por halogênio (por exemplo, flúor), hidroxila ou C~ 1-4~ alcóxi (por exemplo, metóxi).
BRPI0606319-5A 2005-01-21 2006-01-20 compostos farmacêuticos BRPI0606319A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64596305P 2005-01-21 2005-01-21
PCT/GB2006/000206 WO2006077425A1 (en) 2005-01-21 2006-01-20 Combinations of pyrazole kinase inhibitors and further antitumor agents

Publications (1)

Publication Number Publication Date
BRPI0606319A2 true BRPI0606319A2 (pt) 2009-06-16

Family

ID=35966985

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606319-5A BRPI0606319A2 (pt) 2005-01-21 2006-01-20 compostos farmacêuticos

Country Status (11)

Country Link
US (1) US20080161355A1 (pt)
EP (1) EP1845975A1 (pt)
JP (1) JP2008528469A (pt)
KR (1) KR20070107707A (pt)
CN (1) CN101146533A (pt)
AU (1) AU2006207322A1 (pt)
BR (1) BRPI0606319A2 (pt)
CA (1) CA2593475A1 (pt)
MX (1) MX2007008809A (pt)
RU (1) RU2007131101A (pt)
WO (1) WO2006077425A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1651612T3 (pl) 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
MX2007008810A (es) * 2005-01-21 2007-11-21 Astex Therapeutics Ltd Compuestos farmaceuticos.
AR053662A1 (es) * 2005-01-21 2007-05-16 Astex Therapeutics Ltd Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
BRPI0606455A (pt) * 2005-01-21 2008-03-11 Astex Therapeutics Ltd compostos farmacêuticos
CN101133088B (zh) * 2005-03-03 2011-04-13 三菱丽阳株式会社 聚合物粒子、含有它的树脂组合物、成型体
EP1743890A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
US7897589B2 (en) 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743892A1 (en) 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
JP2009536187A (ja) * 2006-05-05 2009-10-08 アステックス・セラピューティクス・リミテッド 癌の処置のための４−（２，６−ジクロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸（１−メタンスルホニル−ピペリジン−４−イル）−アミド
JP2009536186A (ja) * 2006-05-08 2009-10-08 アステックス・セラピューティクス・リミテッド 癌処置のためのジアゾール誘導体の医薬組合せ
EP2043635A2 (en) * 2006-06-29 2009-04-08 Astex Therapeutics Limited Pharmaceutical combinations
JP2009543768A (ja) * 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド 医薬組み合わせ
US20100004243A1 (en) * 2006-07-14 2010-01-07 Astex Therapeutics Limited Pharmaceutical compounds
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
EP2070916A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
EP2070924A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel
US20110224221A1 (en) * 2008-10-01 2011-09-15 Sharpless Norman E Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
AU2009298367A1 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
US20100144687A1 (en) * 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
JP2012526850A (ja) * 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
FR2947546B1 (fr) * 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
AU2010300259A1 (en) 2009-10-01 2012-04-26 Janssen Pharmaceutica Nv Proteasome inhibitors for treating cancer
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
JP2013545758A (ja) 2010-11-17 2013-12-26 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 増殖性キナーゼｃｄｋ４及びｃｄｋ６の阻害による虚血からの腎組織の保護
PE20151280A1 (es) * 2012-12-21 2015-09-12 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
US9487530B2 (en) 2013-03-15 2016-11-08 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
MX2016009226A (es) * 2014-01-15 2016-10-05 Novartis Ag Combinaciones farmaceuticas.
US20150297607A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CA2987552A1 (en) 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors
WO2017030938A1 (en) * 2015-08-14 2017-02-23 Incyte Corporation Heterocyclic compounds and uses thereof
MY195528A (en) 2016-03-17 2023-01-30 Hoffmann La Roche 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar
US20190175598A1 (en) 2016-08-23 2019-06-13 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
JP7219224B2 (ja) 2017-03-16 2023-02-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳癌の治療のための組合せ療法
CN107686477B (zh) * 2017-09-30 2020-01-31 武汉九州钰民医药科技有限公司 作为cdk4/6抑制剂的新型化合物及其应用
CN107652284B (zh) * 2017-09-30 2020-01-31 武汉九州钰民医药科技有限公司 用于治疗增殖性疾病的cdk抑制剂
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
KR102507397B1 (ko) * 2020-09-10 2023-03-07 계명대학교 산학협력단 히스톤 탈아세틸화효소 억제 활성을 갖는 신규 화합물 및 이의 용도
CN112755023B (zh) * 2021-01-22 2023-04-25 湖南师范大学 一种新型表观遗传因子抑制剂2800z在制备肝癌药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282361A (en) * 1978-03-16 1981-08-04 Massachusetts Institute Of Technology Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines
US5164196A (en) * 1987-05-19 1992-11-17 Ventech Research, Inc. Crotoxin complex as cytotoxic agent
US5002755A (en) * 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
US5514665A (en) * 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
US5502068A (en) * 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
WO1997027852A1 (en) * 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU2001241128A1 (en) * 2000-03-14 2001-09-24 Fujisawa Pharmaceutical Co. Ltd. Novel amide compounds
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
CA2442396A1 (en) * 2001-02-28 2002-09-12 Brian C. Giles Method and formula for anti-tumor and anti-matastatic effect
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
JP2005503131A (ja) * 2001-05-11 2005-02-03 ザ バーナム インスティチュート Ｒｉｚに関するスクリーニング、診断および治療の方法
OA12755A (en) * 2002-01-22 2006-07-03 Warner Lambert Co 2-(pyridin-2-ylamino)-pyridoÄ2,3dÜpyrimidin-7-ones.
CN101259120B (zh) * 2002-03-04 2012-07-04 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
AR041291A1 (es) * 2002-09-19 2005-05-11 Schering Corp Imidazopiridinas como inhibidores de quinasa dependientes de ciclina
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
PL1651612T3 (pl) * 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
AR053662A1 (es) * 2005-01-21 2007-05-16 Astex Therapeutics Ltd Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
MX2007008810A (es) * 2005-01-21 2007-11-21 Astex Therapeutics Ltd Compuestos farmaceuticos.
TW200745003A (en) * 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
US20080161355A1 (en) 2008-07-03
CA2593475A1 (en) 2006-07-27
MX2007008809A (es) 2007-09-07
AU2006207322A1 (en) 2006-07-27
WO2006077425A1 (en) 2006-07-27
CN101146533A (zh) 2008-03-19
KR20070107707A (ko) 2007-11-07
JP2008528469A (ja) 2008-07-31
EP1845975A1 (en) 2007-10-24
RU2007131101A (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
BRPI0606319A2 (pt) compostos farmacêuticos
BRPI0606480A (pt) compostos farmacêuticos
BRPI0606455A (pt) compostos farmacêuticos
MEP36508A (en) Triazolopyrazine derivatives useful as anti-cancer agents
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
TW200612950A (en) Quinazolinedione derivatives as PARP inhibitors
DE602005005240D1 (de) 4'-C-substituierte 2-Haloadenosinderivate
CR8755A (es) Derivado de quinolina fusionada y uso del mismo
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
HRP20080113T3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
BRPI0414480A (pt) derivados de 2,4-di(hetero)-arilamino-pirimidina como inibidores de zap-70 e/ou syk
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
WO2008007113A3 (en) Pharmaceutical combinations
ATE542799T1 (de) Chinolinonderivate als parp und tank-inhibitoren
SG151249A1 (en) 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
AR018175A1 (es) Compuestos de indol-3-glioxilamidas sustituidas, utiles como medicamentos antitumorales, composiciones farmaceuticas formuladas con dichos derivados,utilizacion de dichos derivados para la preparacion de medicamentos antitumorales y los medicamentos asi preparados.
BR0208455A (pt) Derivados de glutaramida substituìda com n-fenpropilciclopentila como inibidores de nep para a fsad
DE60324544D1 (de) Muskarin antagonisten
CY1121984T1 (el) Μη-ορμονικοι στεροειδεις ρυθμιστες toy nf-kb για θεραπεια ασθενειας
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
TN2010000130A1 (fr) Derives de quinazolinedione, leur preparation et leurs applications therapeutiques
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
SE0403171D0 (sv) New compounds

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.